Unknown

Dataset Information

0

Interleukin-7 receptor blockade suppresses adaptive and innate inflammatory responses in experimental colitis.


ABSTRACT:

Unlabelled

Background

Interleukin-7 (IL-7) acts primarily on T cells to promote their differentiation, survival, and homeostasis. Under disease conditions, IL-7 mediates inflammation through several mechanisms and cell types. In humans, IL-7 and its receptor (IL-7R) are increased in diseases characterized by inflammation such as atherosclerosis, rheumatoid arthritis, psoriasis, multiple sclerosis, and inflammatory bowel disease. In mice, overexpression of IL-7 results in chronic colitis, and T-cell adoptive transfer studies suggest that memory T cells expressing high amounts of IL-7R drive colitis and are maintained and expanded with IL-7. The studies presented here were undertaken to better understand the contribution of IL-7R in inflammatory bowel disease in which colitis was induced with a bacterial trigger rather than with adoptive transfer.

Methods

We examined the contribution of IL-7R on inflammation and disease development in two models of experimental colitis: Helicobacter bilis (Hb)-induced colitis in immune-sufficient Mdr1a-/- mice and in T- and B-cell-deficient Rag2-/- mice. We used pharmacological blockade of IL-7R to understand the mechanisms involved in IL-7R-mediated inflammatory bowel disease by analyzing immune cell profiles, circulating and colon proteins, and colon gene expression.

Results

Treatment of mice with an anti-IL-7R antibody was effective in reducing colitis in Hb-infected Mdr1a-/- mice by reducing T-cell numbers as well as T-cell function. Down regulation of the innate immune response was also detected in Hb-infected Mdr1a-/- mice treated with an anti-IL-7R antibody. In Rag2-/- mice where colitis was triggered by Hb-infection, treatment with an anti-IL-7R antibody controlled innate inflammatory responses by reducing macrophage and dendritic cell numbers and their activity.

Conclusions

Results from our studies showed that inhibition of IL-7R successfully ameliorated inflammation and disease development in Hb-infected mice by controlling the expansion of multiple leukocyte populations, as well as the activity of these immune cells. Our findings demonstrate an important function of IL-7R-driven immunity in experimental colitis and indicate that the therapeutic efficacy of IL-7R blockade involves affecting both adaptive and innate immunity.

SUBMITTER: Willis CR 

PROVIDER: S-EPMC3551718 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Interleukin-7 receptor blockade suppresses adaptive and innate inflammatory responses in experimental colitis.

Willis Cynthia R CR   Seamons Audrey A   Maxwell Joe J   Treuting Piper M PM   Nelson Laurel L   Chen Guang G   Phelps Susan S   Smith Carole L CL   Brabb Thea T   Iritani Brian M BM   Maggio-Price Lillian L  

Journal of inflammation (London, England) 20121012 1


<h4>Unlabelled</h4><h4>Background</h4>Interleukin-7 (IL-7) acts primarily on T cells to promote their differentiation, survival, and homeostasis. Under disease conditions, IL-7 mediates inflammation through several mechanisms and cell types. In humans, IL-7 and its receptor (IL-7R) are increased in diseases characterized by inflammation such as atherosclerosis, rheumatoid arthritis, psoriasis, multiple sclerosis, and inflammatory bowel disease. In mice, overexpression of IL-7 results in chronic  ...[more]

Similar Datasets

| S-EPMC3269819 | biostudies-literature
| S-EPMC4515997 | biostudies-literature
| S-EPMC6763269 | biostudies-literature
| S-EPMC8369894 | biostudies-literature
| S-EPMC6830508 | biostudies-literature
| S-EPMC11324439 | biostudies-literature
| S-EPMC7578751 | biostudies-literature
2022-11-16 | GSE217899 | GEO
| S-EPMC3409280 | biostudies-literature
| S-EPMC5976516 | biostudies-literature